Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

fabry disease/febre

O link é salvo na área de transferência
ArtigosTestes clínicosPatentes
Página 1 a partir de 36 resultados
Fever of unknown origin (FUO) is a rather rare clinical syndrome representing a major diagnostic challenge. The occurrence of more than three febrile attacks with fever-free intervals of variable duration during 6 months of observation has recently been proposed as a subcategory of FUO, Recurrent

Prevalence of Fabry Disease in Familial Mediterranean Fever Patients from Central Anatolia of Turkey.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Fabry disease (FD) is a progressive, X-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal alpha-galactosidase A (AGALA) activity. FD and familial Mediterranean fever (FMF) have typical clinical similarities, and both diseases may progress to end-stage

Recurrent fever of unknown origin: An overlooked symptom of Fabry disease

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Objective: Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to the absent or deficient activity of lysosomal hydrolase a-galactosidase A (α-Gal A), which leads to the accumulation of its substrates in various organs

A Case of Fabry Disease Presenting with Young Stroke and Fever.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Although it is known that Fabry disease should be included in the differential diagnosis of young stroke and fever of unknown origin, it has not been reported in the literature of stroke with fever as the presentation of Fabry disease. This is relevant because stroke with fever may misguide the

Misdiagnosis of familial Mediterranean fever in patients with Anderson-Fabry disease.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Fabry disease (FD) is an underdiagnosed pathology due to its symptomatology that overlaps with various systemic and rheumatic disorders, including familial Mediterranean fever (FMF). We examined the Mediterranean fever (MEFV) and α-galactosidase A (GLA) genes, whose mutations are responsible for FMF
Fabry disease can cause various neurological manifestations. We describe the case of a Japanese woman with Fabry disease who presented with ischemic stroke, aseptic meningitis, and psychiatric symptoms. The patient had a mutation in intron 4 of her α-galactosidase A gene, which was not detected in

Fabry disease: a rare cause of Fever of unknown origin.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se

Relief of chronic burning pain in Fabry disease with neurotropin.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Neurotropin, an extract from the inflamed skin of vaccinia virus-inoculated rabbits, was effective in the relief of sharp or burning pain induced by pyrexia, hot weather, bathing, or exercise in 2 siblings with Fabry disease. Neither neurotropin nor carbamazepine mono-therapy relieved the episodic

Agalsidase alfa: a review of its use in the management of Fabry disease.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase A; intravenous agalsidase alfa 0.2 mg/kg every other week is indicated for the long-term treatment of patients with confirmed Fabry disease. This article reviews the

The impact of fever/hyperthermia in the diagnosis of Fabry: A retrospective analysis.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
BACKGROUND Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A enzyme, which leads to the accumulation of its substrate, the globotriaosylceramide or Gb3, in many organs and tissues. Main clinical manifestations of FD are neuropathic pain,

[A case of acroparesthesias, asthenia and fever. A new mutation in Fabry's disease].

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Fabry disease is an X-linked hereditary metabolic storage disorder, due to the deficiency in lysosomal alpha-galactosidase A, with the consequent glycosphingolipids accumulation, primarily globotriaosylceramide, at cellular level. Multiorganic involvement occurs progressively, leading to severe

Priapism and Fabry disease: a case report.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A 10-year-old boy presented with priapism of 10 h duration which after unsuccessful conservative measures, was relieved by a saphenocorporeal shunt. A 4-year history of intermittent vague aching of fingers and toes accompanied by low-grade fever was reported. Fabry disease was confirmed by the lack

[Early diagnosis of Fabry disease in children].

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Fabry disease, a rare X-linked lysosomal storage disorder, is caused by deficiency of the enzyme α-galactosidase A. The incidence, ranging from one over 40 000 to one over 11 7000 worldwide is probably underestimated due to its unspecific pattern of presentation. The symptoms, including

Fabry disease simulating Crohn's ileitis.

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Fabry disease is an inherited (X-linked) lysosomal storage disorder caused by deficiency of α-galactosidase A, leading to accumulation of globotriaosylceramide in various tissues. A 57-year-old male with a family history and laboratory findings of Fabry disease, was consulted for severe abdominal
Fabry disease (FD) is an X-linked lysosomal disorder caused by mutations in GLA gene resulting in lack of or faulty α-galactosidase A (α-GalA) enzyme. Enzyme replacement therapy (ERT) with recombinant human α-GalA enzyme (agalsidase) is the standard treatment option for FD. Infusion-related
Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge